- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CTI signs Japan cyclotron export deal
Cyclotron developer CTI of Knoxville, TN, has signed an agreementwith Japan Steel Works for sales of CTI cyclotrons in Japan. JapanSteel Works will import CTI's Radioisotope Delivery System (RDS)111 into Japan and will also provide service for the
Cyclotron developer CTI of Knoxville, TN, has signed an agreementwith Japan Steel Works for sales of CTI cyclotrons in Japan. JapanSteel Works will import CTI's Radioisotope Delivery System (RDS)111 into Japan and will also provide service for the devices.
RDS 111 is a self-shielding cyclotron, with relatively lowweight and compact size, compared with other cyclotrons. CTI reducedthe weight of the system by 50%, to a total weight of 42.5 tons.
Japan Steel Works will sell RDS 111 for ¥200 million to¥400 million ($1.85 million to $3.7 million) depending onoptions, and the company hopes to sell two to three a year, accordingto Nikkei English News.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
